<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5401">
  <stage>Registered</stage>
  <submitdate>31/03/2015</submitdate>
  <approvaldate>31/03/2015</approvaldate>
  <nctid>NCT02408549</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic Clonic Seizures</studytitle>
    <scientifictitle>An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy</scientifictitle>
    <utrn />
    <trialacronym>VALUE</trialacronym>
    <secondaryid>2012-001770-29</secondaryid>
    <secondaryid>EP0012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epilepsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lacosamide Tablet
Treatment: drugs - Lasosamide Oral Solution

Experimental: Lacosamide - Start dose
SP982 completers at V1:
LCM 10 mg/kg/day for pediatric subjects weighing &lt;30 kg
LCM 8 mg/kg/day for pediatric subjects weighing = 30kg to &lt;50 kg
LCM 400 mg/day (200 mg bid) for adult subjects (=18 years of age) or pediatric subjects weighing =50 kg
SP982 Baseline failures at V1:
LCM 2 mg/kg/day for pediatric subjects weighing &lt;50 kg
LCM 100 mg/day (50 mg bid) for adult subjects (=18 years of age) or pediatric subjects weighing =50 kg
Oral solution (pediatric subjects &lt;50 kg):
Minimum LCM dose: 4 mg/kg/day
Maximum LCM dose: 12 mg/kg/day
Tablets (pediatric subjects =50kg):
Minimum LCM dose: 200 mg/day
Minimum LCM dose: 600 mg/day
Tablets (adult subjects):
Minimum LCM dose: 200 mg/day
Maximum LCM dose: 800 mg/day


Treatment: drugs: Lacosamide Tablet
Active substance: Lacosamide
Pharmaceutical form: Tablet
Concentration: 50 mg and 100 mg
Route of Administration: oral administration

Treatment: drugs: Lasosamide Oral Solution
Active substance: Lacosamide
Pharmaceutical form: Oral solution
Concentration: 10 mg/ml
Route of Administration: Oral administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of subjects experiencing at least one Adverse Event (AE) during the study (up to 5 years) - Adverse Events will be reported spontaneously by the subject and/or caregiver or observed by the investigator.</outcome>
      <timepoint>During the study (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects withdrawing due to Adverse Events (AEs) during the study (up to 5 years) - Adverse Events will be reported spontaneously by the subject and/or caregiver or observed by the investigator.</outcome>
      <timepoint>During the study (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of new seizure types during the Treatment Period</outcome>
      <timepoint>During the Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of up to 25% in days with absence seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of &gt;25% to 50% in days with absence seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of &gt;50% to 75% in days with absence seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of &gt;75% in days with absence seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of up to 25% in days with myoclonic seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of &gt;25% to 50% in days with myoclonic seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of &gt;50% to 75% in days with myoclonic seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of subjects with an increase of &gt;75% in days with myoclonic seizures per 28 days during the Treatment Period as compared to the Prospective Baseline (of study SP0982)</outcome>
      <timepoint>From Visit 1 to End of Treatment Period (up to 5 years)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in Primary Generalized Tonic-clonic (PGTC) seizure frequency per 28 days from Combined Baseline - Percent change in PGTC seizure frequency per 28 days from Combined Baseline, where Combined Baseline is defined as the combined 12-week Historical Baseline and 4-week Prospective Baseline periods immediately prior to randomization in the parent study (SP0982).</outcome>
      <timepoint>From Combined Baseline until Termination Visit (up to Week 243)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Subject must have completed or be an eligible Baseline failure from the parent study
        (SP0982). Note: Other subjects screened for SP0982 may be considered for roll-over to
        EP0012 if the investigator considers that the subject could benefit from treatment with
        open-label lacosamide (LCM) and based on prior discussion with and approval from the UCB
        Study Physician or representative.</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject is receiving any investigational drugs or using any experimental devices in
             addition to Lacosamide (LCM)

          -  Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious
             adverse event (SAE)

          -  Subject has an active suicidal ideation as indicated by a positive response ("Yes") to
             either Question 4 or Question 5 of the "Since Last Visit" version of the
             Columbia-Suicide Severity Rating Scale (C-SSRS)

          -  Subject has &gt;=2x upper limit of normal (ULN) of any of the following: alanine
             aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP),
             or &gt;ULN total bilirubin (=1.5xULN total bilirubin if known Gilbert's syndrome). If
             subject has elevations only in total bilirubin that are &gt;ULN and &lt;1.5xULN, fractionate
             bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin
             &lt;35%).

        For randomized subjects with a Baseline result &gt;ULN for ALT, AST, ALP, or total bilirubin,
        a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be
        understood and recorded in the Case Report form (CRF).

        If subject has &gt;ULN ALT, AST, or ALP that does not meet the exclusion limit at screening,
        repeat the tests, if possible, prior to dosing to ensure there is no further ongoing
        clinically relevant increase. In case of a clinically relevant increase, inclusion of the
        subject must be discussed with the Medical Monitor. Tests that result in ALT, AST, or ALP
        up to 25% above the exclusion limit may be repeated once for confirmation. This includes
        re-screening.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Ep0012 980 - Chatswood</hospital>
    <hospital>Ep0012 984 - Clayton</hospital>
    <hospital>Ep0012 985 - Heidelberg</hospital>
    <hospital>Ep0012 981 - Parkville</hospital>
    <postcode> - Chatswood</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Heidelberg</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Florianopolis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Passo Fundo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Blagoevgrad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Changchun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostarva Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Zlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Neustadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Goettingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Radeberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tubingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>New Hyde Park</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovoth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pozzilli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Asaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuishi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gifu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hamamatsu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Itami- City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kagoshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kodaira</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kokubunji</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ohmura</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sapporo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shinjuku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gangnamgu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Zapopan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Czestochowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gliwice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Tyniec Maly</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Vila Real</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Campulung Muscel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targumures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Sankt Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Smolensk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bardejov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Hlohovec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB BIOSCIENCES, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy
      for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects &gt;= 4 years of
      age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM
      SP0982 (NCT02408523) study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02408549</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>UCB Cares</name>
      <address>+18445992273 (UCB)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>